[{"address1": "Warfvinges vag 35", "city": "Stockholm", "zip": "112 51", "country": "Sweden", "phone": "46 86 95 69 30", "website": "https://www.bioarctic.se", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "BioArctic AB (publ) develops biological drugs for patients with disorders of the central nervous system in Sweden. The company develops Lecanemab, Lecanemab AHEAD 3-45, and Lecanemab Back-up for the treatment of Alzheimer's disease. In addition, the company develops AD-BT2802 and AD-BT2803 drug projects against Alzheimer's disease that are being combined with blood-brain barrier technology and Brain Transporter to promote uptake of antibodies into the brain. Further, it develops BAN1503, BAN2802, BAN2803, and AD2603 for the treatment of Alzheimer's disease; ND-BT3814, ND3014, andGD-BT6822 for the treatment of neurodegenerative disease; and PD1601, PD-BT2238, and PD1602 for the treatment of Parkinson's disease. It has research collaboration agreement with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.", "fullTimeEmployees": 96, "companyOfficers": [{"maxAge": 1, "name": "Dr. Gunilla  Osswald Ph.D.", "age": 62, "title": "President & CEO", "yearBorn": 1961, "fiscalYear": 2023, "totalPay": 8750000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. P\u00e4r  Gellerfors", "age": 76, "title": "Co-Founder, Senior VP of Business Strategy & Director", "yearBorn": 1947, "fiscalYear": 2023, "totalPay": 390000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Prof. Lars  Lannfelt", "age": 74, "title": "Co-Founder, Senior VP of Medical science & Director", "yearBorn": 1949, "fiscalYear": 2023, "totalPay": 2544000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anders  Martin-Lof M.B.A., M.Sc.", "age": 52, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Johanna  F\u00e4lting", "age": 51, "title": "Chief Research Officer & Head of Research", "yearBorn": 1972, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christer  M\u00f6ller", "age": 64, "title": "VP of Pre-Clinical Development & Chief Scientific Officer", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Oskar  Bosson", "age": 47, "title": "VP and Head of IR & Communication", "yearBorn": 1976, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Leif  Gallo LL.M.", "age": 64, "title": "General Counsel and Head of Legal & IP", "yearBorn": 1959, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Harald  Borgeke", "title": "Head of Public Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Frida  Lekander", "title": "Head of Marketing", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 14.7, "open": 14.7, "dayLow": 14.7, "dayHigh": 14.7, "regularMarketPreviousClose": 14.7, "regularMarketOpen": 14.7, "regularMarketDayLow": 14.7, "regularMarketDayHigh": 14.7, "beta": -0.191, "volume": 200, "regularMarketVolume": 200, "averageVolume": 237, "averageVolume10days": 285, "averageDailyVolume10Day": 285, "bid": 16.57, "ask": 16.97, "bidSize": 40700, "askSize": 313300, "marketCap": 1439388416, "fiftyTwoWeekLow": 13.89, "fiftyTwoWeekHigh": 28.01, "priceToSalesTrailing12Months": 4.808444, "fiftyDayAverage": 18.036043, "twoHundredDayAverage": 20.835394, "currency": "USD", "enterpriseValue": 979418688, "profitMargins": -0.29490998, "floatShares": 52512796, "sharesOutstanding": 73935504, "heldPercentInsiders": 0.4711, "heldPercentInstitutions": 0.38774, "impliedSharesOutstanding": 90215504, "bookValue": 10.521, "priceToBook": 1.5164908, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -88280000, "trailingEps": -0.1, "enterpriseToRevenue": 3.272, "enterpriseToEbitda": -13.17, "52WeekChange": -0.41255522, "SandP52WeekChange": 0.24014747, "exchange": "PNK", "quoteType": "EQUITY", "symbol": "BRCTF", "underlyingSymbol": "BRCTF", "shortName": "BIOARCTIC AB", "longName": "BioArctic AB (publ)", "firstTradeDateEpochUtc": 1669732200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9a05be1b-6929-339b-ab84-98a817c0a6d2", "messageBoardId": "finmb_23702931", "gmtOffSetMilliseconds": -14400000, "currentPrice": 15.955, "recommendationKey": "none", "totalCash": 489679008, "totalCashPerShare": 5.543, "ebitda": -74368000, "totalDebt": 59705000, "quickRatio": 3.413, "currentRatio": 7.177, "totalRevenue": 299345984, "debtToEquity": 6.424, "revenuePerShare": 3.396, "returnOnAssets": -0.052410003, "returnOnEquity": -0.091800004, "freeCashflow": -524857376, "operatingCashflow": -134203000, "revenueGrowth": 17.42, "grossMargins": 0.72384, "ebitdaMargins": -0.24843, "operatingMargins": -1.50217, "financialCurrency": "SEK", "trailingPegRatio": null, "__fetch_time": "2024-09-05"}]